Vertex Pharmaceuticals Stock Forum

$Verona Pharma (VRNA.US)$ $Safe & Green Development (SGD.US)$ $Globalstar (GSAT.US)$ $SRM Entertainment (SRM.US)$ $Silo Pharma (SILO.US)$ $ESSA Pharma (EPIX.US)$ $SAG Holdings (SAG.US)$ $Tenaya Therapeutics (TNYA.US)$ $Air Transport Services (ATSG.US)$ $Hanryu Holdings (HRYU.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $Singular Genomics (OMIC.US)$ $Nuwellis (NUWE.US)$ $Vast Renewables (VSTE.US)$
📊⚡️📊

$Vertex Pharmaceuticals (VRTX.US)$
yahoo.com/news/...

$SoFi Technologies (SOFI.US)$ 👈🤑🤤📈
$Vertex Pharmaceuticals (VRTX.US)$. $Citigroup (C.US)$

The 13F filing for the hedge fund led by the late Jim Simons (RIP) just dropped and we got you covered
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil (XOM.US)$ : 0.70%
$Boeing (BA.US)$ : 0.43%
$GE Aerospace (GE.US)$ : 0.41%
$Alphabet-C (GOOG.US)$ : 0.31%
$Netflix (NFLX.US)$ : 0.31%
$Disney (DIS.US)$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron (CVX.US)$ : 0.52%...

Keep an eye on these M&As: 👀
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt (ADTX.US)$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics (KTRA.US)$
$Johnson & Johnson (JNJ.US)$ to acquire $ShockWave Medical (SWAV.US)$
$Vertex Pharmaceuticals (VRTX.US)$ to acquire $Alpine Immune (ALPN.US)$
$Century Therapeutics (IPSC.US)$ to acquire Clade Tx
$Eliem Therapeutics (ELYM.US)$ to acquire Tenet Med.
$Incyte (INCY.US)$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals (DCPH.US)$
...

No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals (VRTX.US)$ paid $4.9 bil for $Alpine Immune (ALPN.US)$
$Gilead Sciences (GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...

$Vertex Pharmaceuticals (VRTX.US)$ reported on May 6 first quarter adjusted earnings and revenue that beat analysts' estimates.
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...